The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Gene Therapy in Cancer Treatment: Why Go Nano?
Open accessAbstract
The proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“To circumvent the degradation limitations, miRNA may be modified: miRNA mimics are mainly modified by methylation of the passenger strand and locked nucleic acids (LNA) chemistry is used for modification of anti-miRNA (reviewed in [106]).”
BackgroundMicroenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 1×
“The hypoxia experienced in the tumor induced by the uncontrolled growth of tumor cells, induce the secretion of angiogenesis signals, such as vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiopoietins or IL-8, to assure oxygen and nutrient supply [136,137].”
BackgroundThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081 · cited 1×
“Gene silencing therapy is usually accomplished by introducing siRNA or shRNA in tumor cells designed to target a specific complementary sequence to messenger RNA (mRNA) of a selective gene, inducing its degradation or by blocking protein synthesis [89].”
BackgroundCancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860 · cited 8×
“Regarding tumor progression, CAFs stimulate the growth of tumor cells, induce an immunosuppressive TME and stimulate an increased desmoplasia of the ECM [139,140].”
BackgroundInfluentialGlobal Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765 · cited 2×
“Another limitation is the need of large-scale production of viral vectors and associated quality control performed by highly competent technicians [28,128].”
BackgroundLundstrom, K. (2018) · Diseases · doi:10.3390/diseases6020042 · Cited by 469
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Liu, T., Zhou, L., Li, D., Andl, T., & Zhang, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00060 · Cited by 446
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · cited 1×
“For additional details on non-viral delivery systems, including liposomal formulations, for CRISPR/Cas9-based genome editing please see [209,211,212]).”
BackgroundMuhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165210 · Cited by 410
Rai, R., Alwani, S., & Badea, I. (2019) · Polymers · doi:10.3390/polym11040745 · Cited by 350
Production and clinical development of nanoparticles for gene delivery
Chen, J., Guo, Z., Tian, H., & Chen, X. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.23 · Cited by 274
Jeong, K., Yu, Y. J., You, J. Y., Rhee, W. J., & Kim, J. A. (2020) · Lab on a Chip · doi:10.1039/c9lc00958b · Cited by 178
Drug Delivery with polymeric nanocarriers-cellular uptake mechanisms
Nelemans, L. C., & Gurevich, L. (2020) · Materials · doi:10.3390/ma13020366 · Cited by 173
Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M., Zaks, T. Z., Frederick, J., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2523 · Cited by 144 · cited 5×
“The favorable clinical responses, consisting in mRNA-4157 tolerability at all dose levels tested, suggested the possibility of further clinical trials [254].”
BackgroundInfluentialTargeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106 · cited 1×
“Gold AuNP 1 with NLS 2-peptide-target, designed to inhibit miR-211 and NCL 3 function in AML 4 cells Effective silencing of the NCL/miR-211/NFkB/DNMT1 pathway, with synergistic blockage of AML cell proliferation and colony formation Extension of AML mice survival, lower white blood cells, metastases to lungs and blast…”
BackgroundLipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93
Fibroblasts as Modulators of Local and Systemic Cancer Metabolism
Sanford-Crane, H., Abrego, J., & Sherman, M. H. (2019) · Cancers · doi:10.3390/cancers11050619 · Cited by 77
Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
Mehta, A., Dalle Vedove, E., Isert, L., & Merkel, O. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2665-9 · Cited by 53
Cited by
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Drug Delivery with polymeric nanocarriers-cellular uptake mechanisms
Nelemans, L. C., & Gurevich, L. (2020) · Materials · doi:10.3390/ma13020366 · Cited by 173
Metadata
- Authors
- Roma-Rodrigues, C., Rivas-García, L., Baptista, P. V., & Fernandes, A. R.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-03-05
- Volume
- 12
- Issue
- 3
- Pages
- 233
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3010381651
- Cited by
- 220
- References
- 19
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.